NasoVAX Influenza Vaccine Description
NasoVAX is a recombinant, monovalent intranasal vaccine RD-Ad5-based and is being developed for both seasonal and pandemic use. NasoVAX can activate the humoral, mucosal, and cellular immune arms in unison for a more comprehensive immune response. The data from the Phase 2a trial indicated that NasoVAX was well-tolerated and achieved 100% seroprotection with serum antibody responses comparable to a licensed injected influenza vaccine. Statistically significant increases in mucosal antibodies were noted, as well as a robust T-cell response directed against influenza.
The safety and immunogenicity of NasoVAX, a monovalent intranasal influenza vaccine based on a replication-deficient adenovirus type 5 platform, were evaluated in a placebo-controlled single ascending-dose phase 2a clinical study (ALT-103-201). Sixty healthy adults (18-49 years) received a single intranasal dose of 1×109 viral particles (vp), 1 × 1010 vp, or 1 × 1011 vp of NasoVAX or placebo. Approximately half of the subjects from the highest dose were evaluated between 12 and 14 months after initial dosing for additional immunogenicity assessment. The durability data show that the immune response elicited by NasoVAX was stable, with no overall change in the antibody titer or level of seroprotection over an average of 13 months. The combination of serum antibody, mucosal antibody, and T-cell response with the durability data provides the potential for improved protection against influenza and suggests that NasoVAX could have a more significant impact on flu symptoms and shedding of the influenza virus than currently approved influenza vaccines.
NasoVAX Influenza Vaccine Indication
NasoVAX is indicated to prevent influenza, seasonal.
NasoVAX Influenza Vaccine Dosage
NasoVAX is administered by intranasal spray. The dosage is being evaluated in clinical trials.
NasoVAX Influenza Vaccine News
March 5, 2021 - Vaccines published preliminary findings on the phase 2 clinical trial of NasoVAX. NasoVAX appeared safe and elicited a broad immune response, including humoral, cellular, and mucosal immunity, with no impact of baseline anti-adenovirus antibody at the most immunogenic dose.
June 1, 2020 - Altimmune Launches Clinical Trial Of T-COVIDTM, An Investigational Intranasal Immune Modulator For The Treatment Of Patients With Early COVID-19. The FDA has agreed that the Company may use its existing lot of RD-Ad5-based NasoVAX influenza vaccine for the planned T-COVID clinical trial,allowing the Company to initiate the study immediately
NasoVAX Influenza Vaccine Clinical Trials
NasoVAX Influenza vaccine continues to be studied in Clinical Trials.